The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia

Xiaolu Zhang¹, Jiping Zeng², Minran Zhou¹, Bingnan Li³,⁴, Yuanyuan Zhang¹, Tao Huang¹,³, Lixiang Wang³, Jihui Jia³ and Chunyan Chen¹*

Abstract

Background: Recent evidence has accumulated that MicroRNA (miRNA) dysregulation occurs in the majority of human malignancies including acute myeloid leukemia (AML) and may contribute to onco-/leukemo-genesis.

Methods: The expression levels of miR-370 and FoxM1 were assessed in 48 newly diagnosed AML patients, 40 AML patients in 1st complete remission (CR) and 21 healthy controls. Quantitative real-time PCR, western blots, colony formation assay, and β-Galactosidase (SA-β-Gal) staining were used to characterize the changes induced by overexpression or inhibition of miR-370 or FoxM1.

Results: We found that the down-regulation of miR-370 expression was a frequent event in both leukemia cell lines and primary leukemic cells from patients with de novo AML. Lower levels of miR-370 expression were found in 37 of 48 leukemic samples from AML patients compared to those in bone marrow cells derived from healthy adult individuals. Ectopic expression of miR-370 in HL60 and K562 cells led to cell growth arrest and senescence. In contrast, depletion of miR-370 expression using RNA interference enhanced the proliferation of those leukemic cells. Mechanistically, miR-370 targets the transcription factor FoxM1, a well established oncogenic factor promoting cell cycle progression. Moreover, when HL60 and KS62 cells were treated with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor, miR-370 expression was up-regulated, which indicates epigenetic silencing of miR-370 in leukemic cells.

Conclusions: Taken together, miR-370 may function as a tumor suppressor by targeting FoxM1, and the epigenetic silence of miR-370 thus leads to derepression of FoxM1 expression and consequently contributes to AML development and progression.

Keywords: miR-370, FoxM1, AML, Cellular senescence

Introduction

Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic haematopoietic diseases characterized by proliferation and maturation arrest of myeloid blasts in bone marrow and blood [1]. The long-term overall survival (OS) rate for AML patients under the age of 60 years and 60 years or older is 30–40% and under 10%, respectively [2], which remains a challenge. Thus, it is urgently needed to search for new targets for molecularly designed therapies.

© Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
functions have thus far been ascribed to specific miRNAs [13]. Moreover, miRNAs have emerged as critical regulators of hematopoiesis and their aberrant expression has been associated with the pathogenesis of leukemia [14]. Functional validation of deregulated miRNAs in hematopoiesis has been shown for several miRNAs [15]. Distinctive patterns of increased expression and/or silencing of multiple miRNAs have been associated with specific cytogenetic and molecular subsets of AML [16]. miR-370 has been noted to be down-regulated in papillary thyroid carcinoma, colorectal cancer [17] and malignant cholangiocytes [18], but evidence of a biological role for this miRNA in AML has not been reported. In the present study, we sought to define the role of miR-370 in AML by investigating its expression and biological function in leukemic cell lines and blast cells from patients with de novo AML.

Results
Down-regulation of miR-370 expression in BM blasts from de novo AML patients
We analyzed miR-370 expression in BM samples from 48 de novo AML patients at diagnosis time using qRT-PCR. As shown in Figure 1A, the miR-370 level in patients’ samples was significantly reduced (P < 0.01, t test) compared to that from healthy controls, while following acquisition of CR in the induction chemotherapy, miR-370 expression level restored to 0.82 fold of controls. There was no association between the presence of mature miR-370 and age, gender, blast percentage or FAB subtypes (data not shown). In six patients, BM samples were available both at diagnosis time prior to treatment and after a complete remission and we found a lower miR-370 level at diagnosis while at least 2.1-fold increase in miR-370 expression after CR (Figure 1B).

Changes in proliferation and cellular senescence of leukemic cells mediated by altered miR-370 expression
We then explored the biological function of miR-370 in leukemic cells. Cells were transfected with precursors to miR-370 and miR-370 inhibitor to enhance and decrease mature miR-370 expression, respectively. Transfection with the miR-370 precursor increased mature miR-370 expression 114.5 ± 5.70: 1 ± 0.12 (p < 0.05) (pSilencer-miR vs pSilencer) times higher in HL60 and K562 cells, respectively (Figure 2A). Overexpression of miR-370 decreased cell proliferation (Figure 2C and Additional file 1) (pSilencer vs pSilencer-miR: HL60: 88 ± 15 vs 11 ± 4, p < 0.01; K562: 49 ± 5 vs 18 ± 5, p < 0.01). On the other hand, transfection with the miR-370 inhibitor suppressed mature miR-370 expression to 31% ± 0.04 (p < 0.05) and 58% ± 0.05 (p < 0.05) lower in HL60 and K562 cells, respectively (Figure 2B). The decline in miR-370 expression was coupled with enhanced cell proliferation (Figure 2C) (pSuper vs pSuper-miR-inhibitor: HL60: 56 ± 7 vs 72 ± 6, p < 0.05; K562: 66 ± 12 vs 93 ± 7, p < 0.05).

The above result suggests that miR-370 suppresses proliferation of HL60 and K562 cells. We further wanted to define the mechanism behind miR-370 overexpression-mediated proliferation inhibition. We suspected that miR-370 might trigger cellular senescence program. Senescence-associated β-Gal staining, a specific marker for senescent cells [19], was thus performed. A positive

![Figure 1: Downexpression of miR-370 in de novo AML patients. (A) miR-370 expression by qRT-PCR in 48 de novo AML patients, 40 AML patients of 1st CR and 21 healthy controls. (B) Restoration of miR-370 expression in six patients after complete remission achievement in induction chemotherapy. The results are shown as miRNA expression after normalization with U6 and -ΔCt calculations.](http://www.molecular-cancer.com/content/11/1/56)
β-Gal staining was observed in the two cell lines transfected with miR-370 precursors (Figure 2D) [pSilencer vs pSilencer-miR (% of β-Gal-positive cells): HL60: 3 ± 1 vs 28 ± 3, p < 0.01; K562: 8 ± 3 vs 40 ± 1, p < 0.01].

Up-regulation of miR-370 expression mediated by 5-Aza-CdR
DNA methylation is an epigenetic modification that regulates gene expression. Aberrant DNA甲基化 has
been implicated in many cancers [20]. Global hypomethylation or aberrant hypermethylation of gene promoter CpG islands result, respectively, in tumor cell genomic instability and gene silencing, particularly of tumor suppressor genes [17]. Interestingly, the chromosomal location of miR-370 on chromosome 14q32.31 has been shown to be regulated by DNA methylation, or deleted by loss of heterozygosity [14,21] or by hypermethylation of an CpG island 200 bp upstream in the mother allele [22]. Treatment with 5 μM 5-aza-CdR, a DNA methylation inhibitor, for 72 hours, substantially (>2.0-fold) and significantly (P < 0.05) increased the expression of miR-370 in both HL60 and K562 cells (Figure 3A) and decreased cell proliferation (Figure 3D) (control vs CdR: HL60: 24 ± 4 vs 7 ± 2, p < 0.01; K562: 152 ± 5 vs 78 ± 5, p < 0.001).

Identification of FoxM1 as a target for miR-370

To further elucidate the mechanism by which miR-370 affected cellular senescence and proliferation, we next screened for potential targets of miR-370 using four target prediction programs with different algorithms: DIANA-MicroT [23], TargetScan [24], Miranda [25] and PicTar [26]. All potential targets predicted by more than one of these programs were identified. We selected the forkhead box M1 (FoxM1) for further study because of its well-characterized role in tumor biology. The FoxM1 gene has a 249-bp 3′UTR region that presents a 7-mer binding site for miR-370 (Figure 4A).

First, we made the luciferase reporter constructs containing the miR-370 recognition sequence from the 3′-UTR of FoxM1 inserted downstream of the luciferase gene. Transfection with miR-370 precursor decreased reporter activity in K562 cells (Figure 4B), which strongly indicates that FoxM1 is a target for miR-370. Next, the studies were repeated with random mutations in the recognition sequence (Figure 4A), which resulted in abolition of the reporter activation by miR-370 precursor (Figure 4B). Finally, we assessed the effect of miR-370 expression on FoxM1 expression. Transfection of HL60 and K562 cells with miR-370 precursor resulted in lower expression of FoxM1 after 48 hours (Figure 4C-D). Concomitant with decreased FoxM1 expression, there was reduction of its downstream target c-myc and skp2 (Figure 4C-D). There was a >2-fold increase in expression of FoxM1 in HL60 and K562 cells after transfection of miR370 inhibitor plasmids (Figure 4E). 5-aza-CdR significantly reduced the expression of FoxM1 in both HL60 and K562 cells (Figure 3 B-C). These changes were similar to those observed with miR-370 overexpression. Taken together, FoxM1 is a target of miR-370.

Overexpression of FoxM1 in de novo AML patients

FoxM1, a master regulator of mitotic gene expression, is required for cell proliferation and its inhibition leads to reduction in anchor-independent growth and tumorigenesis of cancer cells [27]. As we have verified that FoxM1 is a target for miR-370, we then sought to probe its role in AML. The tumor specimens from forty-eight de novo AML patients and forty AML patients in 1st CR and twenty-one healthy controls were analyzed for FoxM1 mRNA expression using qRT-PCR. Patient characteristics are described in Table 1. The FoxM1 transcript level in AML patients was found 21.47-fold higher than that in controls, while following acquisition of CR in the induction chemotherapy, FoxM1 expression level reduced to 1.75 fold of controls. (Figure 5 A, C), which was negatively correlated with miR-370 levels. There was a highly significant difference in FoxM1 expression between AML samples, CR samples and healthy controls (qRT-PCR, One-Way ANOVA, p < 0.01). In six patients, BM samples were available both at diagnosis time prior to treatment and after a complete remission and we found a higher FoxM1 level at diagnosis while a significant decrease in FoxM1 expression after CR except one sample (Figure 5B). There was no clear association between the presence of FoxM1 mRNA and age, gender, tumor burden or FAB subtypes (data not shown). Moreover, BM materials from 8 de novo AML patients, 8 patients in 1st CR and 5 healthy controls randomly chosen from our AML patient pool were used to determine the mRNA expression level of c-Myc, hTERT, p27kip1 and skp2, all of which were the target genes of FoxM1, using real-time PCR method. We found that the transcript levels of c-Myc, hTERT and skp2 in AML patients were respectively 9.64, 3.76 and 3.14-fold higher than those in controls, while following acquisition of CR, all of them reduced almost to the same levels of
controls. On the contrary, the expression level of \textit{p27kip1} in AML patients is only 40% of that in controls, while restored after CR (Additional file 2).

**Defective foci formation by depletion of FoxM1 in AML cell lines**

Then, we employed the FoxM1-specific siRNA to knock down FoxM1 expression in AML cell lines and the cells were then assessed for their clonogenic capacity. Efficient silence of FoxM1 expression in these cells was verified using qRT-PCR and Western blot analyses (Figure 5 D-E). Compared to the control cells, the FoxM1-knocked down cells exhibited significantly diminished foci formation (Figure 5F) (Controls vs FoxM1 siRNA: HL60: 19 ± 3 vs 11 ± 2, \( p < 0.05 \); K562: 33 ± 5 vs 5 ± 2, \( p = 0.001 \)). Following FoxM1 depletion, its target genes \( c\text{-}myc \), \( skp2 \) and \( hTERT \) were also down-regulated and coupled with the accumulation of the CDK inhibitor \( p27kip1 \) (Figure 5 D-E).

Collectively, the \textit{FoxM1} gene is aberrantly activated in AML and is required for sustained proliferation of the cancer cells.

**Discussion**

In the present study, we explored the expression and role of miR-370 in AML. Our findings show a down-regulation of miR-370 in blasts from patients with de novo AML. Moreover, we identified FoxM1 as a target for miR-370 and restored expression of miR-370 reduced the level of FoxM1. In hematological malignancies a link with miRNA was initially described in chronic lymphocytic leukemia (CLL) by Calin et al. [28]. A cluster of two miRNAs, miR-15a, and miR-16, was found to be located within the deleted region at 13q14, and down-
regulated in the majority (70%) of CLL samples. Notably, miR-15a and miR-16-1 down-regulation contribute to malignant transformation by up-regulating BCL2 [29]. Recently, involvement of miRNA in AML has been documented identifying that miRNA expression profiles are AML subtype-specific and suggesting a pathogenetic role of miRNA in AML. For example, Mi and colleagues [30] showed distinct miRNA signatures between acute lymphoblastic leukemias (ALLs) and AMLs. In that study, patients with AML could be separated from those with ALL on the basis of 21 up-regulated and 6 down-regulated miRNAs, among which four of them (let-7b, miR-128a, miR-128b and miR-223) were the most discriminatory [31]. According to Amanda Dixon-McIver, compared with other major cytogenetic subgroups of AML, APLs bearing the t(15;17) translocation were characterised by the up regulation of 7 miRNAs transcribed from genes located at the 14q32 region. The set includes miR-127, miR-154, miR-154*, miR-299, miR-323, miR-368, and miR-370. Two other groups reported...
independently that miR-155 was up-regulated in AML patients with FLT3-ITD, suggesting that this miRNA contributes to the highly proliferative phenotype of this molecular subset of AML [31-33]. In the present study, we haven’t got the conclusion that the expression level of miR-370 is with AML subtype-specificity, which may be due to the limited number of primary AML patients enrolled in our study.

DNA methylation is an epigenetic modification that can regulate gene expression. Aberrant DNA methylation has been implicated in many cancers [21]. miR-370 and many other miRNAs are organised in clusters together on chromosome 14q32 [34]. This miRNA cluster acts as imprinted non-coding RNA (ncRNA) genes, which are mono-allelically expressed in a parent-of-origin manner (their expression is restricted to either the maternal or the paternal allele). Interestingly, as for this miRNA cluster, which is of maternal origin, its imprinted expression is regulated by an intergenic differentially methylated region (DMR) located ~ 200 kb upstream from the miRNA cluster [24]. Hypermethylation of DMR causes silence of this miRNA cluster, including miR-370. It has been suggested that miRNAs in this region act as tumour repressor genes and that changes in the methylation status of their promoters could trigger cancer development [35]. For instance, miR-127 has been shown to be down regulated or silenced in cancer cells, whose expression is correlated with the methylation and acetylation status of its promoter. Inhibition of methylation and histone deacetylation in these cancer cells causes over expression of miR-127 and related down regulation of the target BCL6, a bona fide protooncogene [36]. We hypothesize that miR-370 also acts as a tumor suppressor in AML, as in papillary thyroid carcinoma, colorectal cancer and malignant cholangiocytes. The comparison of the leukemia samples with healthy controls highlighted the differential expression of miR-370. Following the treatment with 5-aza-2’-deoxycytidine, there is a significant enrichment for miR-370 in AML cell lines, which indicated that hypermethylation may contribute to reduction of miR-370.

Cancer therapy has traditionally relied on cytotoxic treatment strategies on the assumption that complete cellular destruction of tumors optimizes the potential for patient survival. Although these approaches produce complete cell death within a tumor, they also can cause severe side effects in patients [37]. Recently, a promising approach to preventing continued tumor growth is therapy-induced senescence (TIS) [38]. Senescent cells remain viable and metabolically active but are permanently growth arrested [39]. Evidence has recently accumulated that cellular senescence is a potent barrier to cancer development. Our results indeed demonstrated that senescence occurred in most of AML cells treated with miR-370 overexpressing plasmid, which was concomitant with their diminished clonogenic capacity. Given a critical role for senescence induction in tumor suppression and therapeutic efficacy of cancer treatment, the present findings have important biological and clinical implications. All these results suggest that downregulation of miR-370 may be another mechanism involved in the pathology of AML and therefore, could be used as a diagnostic marker and therapeutic target in AML.

We have also analyzed the correlation between miR-370 expression and FoxM1 mRNA expression in 48 de novo AML samples. Consistent with the cell line data, FoxM1 was enriched in the primary blasts miRNAs that inversely correlated to miR-370 expression levels. This result was also observed at the protein level in a few primary AML samples. However, further studies using large numbers of primary AML samples will be needed to confirm this interaction.

**Conclusion**

We demonstrate that miR-370 is a tumor suppressive factor by targeting multiple critical oncogenic pathways. Restoring miR-370 expression downmodulates FoxM1,
induces senescence, and dampens cell growth in AML cells, thereby suggesting miRNA-based therapy as a novel approach to increase response in AML.

**Materials and methods**

**Patients and bone marrow samples**

Forty-eight newly diagnosed AML patients (31 male and 17 female; median age at diagnosis 41; range 14–74), forty AML patients in 1st complete remission (CR) and twenty-one healthy controls were enrolled in this study. Diagnosis of AML was established according to clinical presentation and morphologic criteria of the French-American-British (FAB) Classification. The study was approved by the local ethics committee. Patients’ BM samples were collected between April 2008 and September 2011 at the Department of Hematology, Qilu Hospital, Shandong University, Jinan, China. Mononuclear cells were isolated using Ficoll-Hypaque density gradient centrifugation, and then stored at −80°C until use. All patients and healthy controls were tested for miR-370 and FoxM1 mRNA levels in their BM cells. Among those AML patients, six were analyzed for miR-370 and FoxM1 mRNA.

Figure 5 Overexpression of FoxM1 in de novo AML patients and defective foci formation induced by depletion of FoxM1 in AML cell lines. (A) and (C) Expression of FoxM1 mRNA and protein in de novo AML patients, AML patients of 1st CR and controls, were determined using qRT-PCR and Western blot respectively. (B) Decrease of FoxM1 expression in six patients after complete remission achievement in induction chemotherapy. (D) and (E) FoxM1 depletion triggers concomitant down-regulation of c-myc, hTERT and skp2 coupled with the accumulation of the CDK inhibitor p27kip1 in AML cells. The cells were transfected with either control or FoxM1 siRNA and harvested after 72 hours. qRT-PCR and western blot were applied to detect mRNA and protein levels, respectively. (F) Diminished foci formation of FoxM1-depleted AML cells. The cells were first treated as above and the efficient FoxM1 knock down was verified in (D) and (E).
FoxM1 levels in their bone marrow samples at both diagnosis and complete remission.

Cell lines and culture conditions
Human AML cell lines HL60 and K562 were cultured at 37°C, 95% air, 5% CO2 in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), 100 μg/mL penicillin, and 50 μg/mL streptomycin. To assess 5-aza-CdR (Sigma, Santa Clara, CA, USA) effects, cells were grown on 6-well plates, treated with 5 μM 5-aza-CdR or cold phosphate-buffered saline (PBS) controls for 72 h at 37°C, and then harvested for isolation of total mRNA or protein.

RNA extraction and quantitative real-time PCR
Total cellular RNA in BM samples and in cells with different treatments was extracted using the Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. cDNA was synthesized using random primers (N6) (Fermentas, St. Leon-Rot, Germany) and MMLV reverse transcriptase. The PCR primers used in the study were as follows: sequences specific for FoxM1 mRNA: 5'-TGCAGCTAGGATGTGATCC-3' (Forward) and 5'-GGAGCCATGTCAGACAAT-3' (Reverse). Skp2: 5'-GGACCCTAATGTAGACTAT-3' (Forward) and 5'-CAGCCACCCTATGATCCTT-3' (Reverse); p27kip: 5'-ATGTCAATACTGAGGTGCTCT-3' (Forward) and 5'-TTAGTTTTACGTCTCCTGAGG-3' (Reverse); hTERT: 5'-CGGAAAGATGTGTCCATTGACCAA-3' (Forward) and 5'-GGATGAAAGCGGAGTCTGAGA-3' (Reverse); c-MYC: 5'-TACCCTCTCAAGCAGACAGCTGCACCACACTCT-3' (Forward) and 5'-TACTCTCTGTTTGCTCTGAGG-3' (Reverse). The above primer pairs cross intron/exon boundaries; thus, the resultant PCR products do not represent genomic DNA contamination. β-actin expression was used as a control for RNA loading and RT efficiency and amplified. Quantitative real-time polymerase chain reaction (qRT-PCR) was carried out in an ABI7000 sequence detector (Applied Biosystems, Foster City, CA, USA).

TaqMan qRT-PCR miRNA analysis
Quantification of mature miRNAs was performed using qRT-PCR with the TaqMan miRNA assay kit (Applied Biosystems, Foster City, CA, USA) according to manufacturer’s instruction. Briefly, 10 ng of total RNA was reverse-transcribed (RT) with specific primers, subsequently 1.5 μL of RT product was used as template for real-time PCR. All real-time experiments were performed in triplicate. Data were normalized by the expression of small nuclear RNA (snRNA) U6 and expressed either as relative expression (2-ΔΔCt) or as fold change relative to control (2^ΔΔCt).

Western blot
Total cellular proteins were extracted from cultured cells or BM samples. Proteins were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were probed with the specific antibodies against FoxM1, p27, c-MYC (Santa Cruz Biotehnologies, Santa Cruz, CA, USA), followed by anti-mouse or rabbit horseradish peroxidase–conjugated IgG and developed with the enhanced chemiluminescence method (ECL). β-actin served as a loading control.

miR-expressing and miR-inhibiting plasmids
To generate the miR-expressing pSilencer3.1-H1 neo vector, a fragment of 212 base pairs (bp) corresponding to the desired miRNA and the surrounding sequences was amplified from human genomic sequence, adding a BamHI site and a HindIII site to the 5’ and 3’ ends respectively, using the polymerase chain reaction (PCR) with primers sense: 5’ AAGGGATCTTACTTGGAG GATGGGCGATA 3’ and antisense 5’ TCAAAGCTTC CGGAAGCTCTGTTAGAC 3’. We included a large portion of miRNA surrounding sequence in the attempt to allow correct processing of the miRNA to its mature form and to induce overexpression while preserving a physiologic mechanism of miRNA production. miR-370 inhibitor sequences were synthesized as DNA oligonucleotides; after annealing, were sticking ended and subcloned into a pSuper vector.

Transfection
Cells were incubated in 6-well plates (3.0×10^5/well) overnight and were then transfected with plasmid or siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Chemical modified Stealth small interfering RNA (siRNA) targeting FoxM1 and control siRNA were bought from Invitrogen. The sequence for the FoxM1 siRNA was 5’-GACAACUGUAAGUGUAC UACUU-3’.

Soft agar colony formation assay
HL60 and K562 cells were resuspended in DMEM (Gibco, Carlsbad, CA, USA) containing 20% heat-inactivated fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) with equal amount of either 0.3% agar (HL60 cells) or 0.5% agar (K562 cells), and plated in 6-well plates at 5,000 per well on top of a 2 mL precast semisolid 1% agar underlayer as described previously [40]. The number of colonies with more than 50 cells was counted after two weeks.

Senescence-associated β-Galactosidase (SA-β-Gal) staining
SA-β-Gal staining was done as described [19,41]. Briefly, the cells grown in 6-well plates were transfected with
pSilencer or pSilencer-miR-370. After 7 days, the cells were rinsed with PBS once, fixed in 3% of formaldehyde for 15 min, and incubated with freshly prepared SA-β-Gal staining solution at 37°C overnight.

Luciferase reporter vector
The precursor to miR-370 was synthesized and cloned in pSilencer. Firefly luciferase reporter vectors with the intact putative miR-370 recognition sequence from the 3’-UTR of FoxM1 (pGL3-FoxM1-wt-3’-UTR) or with random mutations (pGL3-FoxM1-mut-3’-UTR) cloned downstream of the firefly luciferase gene were constructed. Wild-type and mutant inserts were confirmed by sequencing. For the 3’UTR-luciferase assays, cells were cotransfected with 0.5 μg pGL3-FoxM1-wt or mut-3’-UTR construct, 4 μg of pSilencer or pSilencer-miR and 0.05 μg pRL-TK Renilla luciferase expression construct using Lipofectamine 2000. Luciferase assays were performed 24 h after transfection using the Dual Luciferase Reporter Assay system (Promega, Madison, Wisconsin, USA).

Statistical analyses
The difference in miR-370 and FoxM1 mRNA expression among different patient groups as detected using qRT-PCR was analyzed using One-Way ANOVA. The comparison of foci numbers, β-Gal-positive cells, luciferase activity and miR-370, FoxM1, c-myc, hTERT, p27, skp2 mRNA expression after different treatments was made using a Student’s t-test. All the tests were two-tailed and computed using SPSS11.5 software. Results are depicted as the mean ± standard error of the mean. P values < 0.05 were defined as statistical significance.

Additional files

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Competing interests
The authors declare no competing financial interests.

Authors’ contributions
JZ, CC and XZ designed the study; XZ, JZ, BI, MZ, YZ and TH performed the research; XZ, JZ, LW, JJ, and CC analyzed and interpreted data; and XZ, JZ, and CC wrote the paper. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by the National Natural Science Foundation of China (Nos. 81170514, 30971151, 81172354, 30972775 and 81001098), the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (The Project-sponsored by SRF for ROCS, SEM), Shandong Provincial Natural Science Foundation, China (Nos. ZR2009CM002, ZR2009CZ001, ZR2010HZ003 and ZR2012HZ003), Independent Innovation Foundation of Shandong University (IIFSDU, Nos. 2010TS074 and 2012TS106) and the National Basic Research Program of China (973 Program, 2012CB911202).

Additional file 1: Proliferation curve of HL60 cell line (A) and K562 cell line (B) after transfection with miR-370 expressing plasmid or the control pSilencer vector. 1 × 10⁷/ml cells were plated in 6-well plates just before the transfection. The number of viable cells was counted at 24 h and 48 h points using trypan blue. Data represents mean ± s.e. from three separate experiments. **p < 0.01 Student’s t-test.

Additional file 2: c-Myc, hTERT, p27kip1 and skp2 expression by qRT-PCR in 8 de novo AML patients, 8 AML patients of 1st CR and 5 healthy controls. The transcript levels of c-Myc, hTERT and skp2 in AML patients were found respectively 9.64, 3.76 and 3.14-fold higher than those in controls, while following acquisition of CR in the induction chemotherapy, all of them reduced almost to the same levels of controls. On the contrary, the expression level of p27kip1 in AML patients is only 40% of that in controls, while restored after CR. *p < 0.05 One-Way ANOVA.

References
1. Estey E, Döhner H: Acute myeloid leukaemia. Lancet 2006, 536:1894–1907.
2. Estey E: Treatment of acute myeloid leukaemia. Haematologica 2009, 94:10–16.
3. Attia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschi T, Margallit H: Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005, 33:2697–2706.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281–297.
5. He L, Hanson GI: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522–531.
6. Cheng AM, Byrom MW, Shelton J, Ford LP: MicroRNA regulates insulin secretion. Nature 2004, 432:226–230.
7. Baltimore D, Boldin MP, et al: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2003, 101:2999–3004.
8. Richardson JA, Olson EN: A pancretic islet-specific microRNA regulates insulin secretion. Nature 2004, 432:226–230.
9. Calin GA, Sevignani C, Dumitru CD, et al: MicroRNA signatures in human cancers. Nat Rev Cancer 2005, 6:857–866.
10. Starczynowski DT, Morin M, et al: Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595–607.
11. Baltimore D, Boldin MP, et al: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:587–598.
12. Calin GA, Croce CM: MicroRNA in human cancers. Nat Rev Cancer 2006, 6:587–605.
13. Baltimore, Boldin MP, et al: MicroRNA: new regulators of immune cell development and function. Nat Immunol 2008, 9:839–849.
14. Marcucci G, Mrozek K, Radmacher MD, et al: Genome-wide identification of microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595–607.
15. Baltimore D, Boldin MP, et al: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:587–598.
16. Baltimore, Boldin MP, et al: MicroRNA: new regulators of immune cell development and function. Nat Immunol 2008, 9:839–849.
17. Marcucci G, Mrozek K, Radmacher MD, et al: Genome-wide identification of microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595–607.
18. Baltimore D, Boldin MP, et al: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:587–598.
19. Baltimore, Boldin MP, et al: MicroRNA: new regulators of immune cell development and function. Nat Immunol 2008, 9:839–849.
20. Marcucci G, Mrozek K, Radmacher MD, et al: Genome-wide identification of microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595–607.
colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29–39.
18. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocyties. Oncogene 2008, 27:2578–2586.
19. Dimri GP, Lee X, Basile G, Acosta M, Sco G, Roskelley C, Medrano EE, Lenskii M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92:9363–9367.
20. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005, 2:54–51.
21. Calin G, Croce C. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25:6202–6210.
22. Hin R, Jrm C. Non-coding RNAs in imprinted gene clusters. Biol Cell 2008, 100:149–166.
23. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004, 18:1165–1178.
24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15–20.
25. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol 2004, 2:1862–1879.
26. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, Padda-I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495–500.
27. Wenger A, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007, 388:1257–1274.
28. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. Frequent deletions and down-regulation of microRNA genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524–15529.
29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al. mir-15 and mir-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944–13949.
30. Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:19971–19976.
31. Garzon R, Volinia S, Liu C-G, Fernandez-Cyiernier G, Palumbo T, Bloomfield, Marcucci G, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:383–389.
32. Garzon R, Garofalo M, Martelli MP, Briesswitz R, Wang L, Fernandez-Cyiernier G, Volinia S, Liu C-G, Schottler S, Haferlach T, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945–3950.
33. Jongen-Lavriscencic M, Sun SM, Dijkstra MK, Valk PJM, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078–5085.
34. Seitz H, Royo H, Bortolin M-L, Lin S-P, Ferguson-Smith AC, Cavaille J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 2004, 14:1741–1748.
35. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435–443.
36. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004, 432:635–639.
37. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010, 102:1536–1546.
38. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003, 63:2706–2715.
39. Campisi J, Fagagna FA. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729–740.
40. Li X-N, Parikh S, Shu Q, Jung H-L, Chow C-W, Perhaky L, Leung H-CE SJ, Blaney S, Lau CC. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 2004, 10:1150–1159.
41. Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM, Bjorkholm M, Teh BT, Nordenskjold M, Xu D. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003, 63:1743–1747.